Nure.Ns

NURE.NS exhibits a strong capital structure with a debt-to-equity ratio of 0.03, indicating minimal leverage and a conservative financing approach. The company's liquidity position is characterized as medium, with a current ratio of 15.32, suggesting a robust ability to meet short-term obligations. However, the company has no cash and equivalents on its balance sheet, and its operating cash flow is negative at -190.83 million INR, which raises concerns about its short-term liquidity.

In terms of profitability, NURE.NS reports a net income of 8.46 million INR despite a significant operating loss of -98.78 million INR. The return on equity (ROE) is 0.44%, and the return on assets (ROA) is 0.4%, both of which are below the industry median for medical equipment and supplies firms. The company's gross profit margin is 37.8%, which is in line with the industry average, but its operating margin is negative, indicating inefficiencies in cost management.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the risk of revenue volatility due to regional economic or regulatory changes. The absence of segment-specific data limits the ability to assess the performance of different product lines or geographic regions.

Looking at the growth trajectory, NURE.NS has reported a revenue of 1,096.61 million INR in the latest period. However, the company's operating cash flow is negative, and its capital expenditures are -23.15 million INR, suggesting a focus on cost reduction rather than expansion. The company's free cash flow is positive at 8.69 million INR, but this is insufficient to offset the operating cash outflow. The outlook for the next fiscal year is uncertain, with no clear indication of revenue growth or improvement in operating performance.

The risk assessment for NURE.NS highlights a medium liquidity risk due to the negative operating cash flow and the absence of cash and equivalents. The dilution risk is low, as the company has not issued additional shares recently, and there is no indication of a dilutive event in the near term. However, the company's net cash position is negative after subtracting total debt, which could lead to increased borrowing costs or a need for equity financing in the future.

Recent events and filings do not provide specific details on the company's strategic initiatives or financial performance. The lack of detailed disclosures in the latest filings and transcripts limits the ability to assess the company's future prospects. The company's financial statements do not mention any significant legal or regulatory issues, but the absence of cash and equivalents is a red flag that requires further investigation.